Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 1;106(10):2006-2018.
doi: 10.1097/TP.0000000000004208. Epub 2022 Jun 29.

Relatively Poor Long-term Outcomes Following Liver Transplantation for NASH in the United States

Omar K Jamil  1 , Burhaneddin Sandikçi  2 , Nolan Faust  3 , Thomas G Cotter  4 , Sonali Paul  1 , Diego di Sabato  5 , John Fung  5 , Michael Charlton  1
Affiliations

Relatively Poor Long-term Outcomes Following Liver Transplantation for NASH in the United States

Omar K Jamil et al. Transplantation. .

Abstract

Background: Nonalcoholic steatohepatitis (NASH) continues to increase in frequency as an indication for liver transplantation (LT). Data on long-term outcomes for these patients are limited. We aimed to compare long-term patient and graft survival in patients undergoing LT for NASH in the United States to other indications.

Methods: We analyzed data from the Scientific Registry of Transplant Recipients of adult patients who underwent primary deceased-donor LT from January 1, 2005, to December 31, 2019.

Results: NASH has increased as an indication for LT by 4.5-fold, from 5.2% in 2005 to 23.4% in 2019. Patient (61.2%) and graft survival (59.2%) at 10 y are significantly poorer for NASH than for all other indications other than alcohol. Patients transplanted for NASH have higher body mass index (32.2 versus 27.6) and greater frequency of diabetes (13% versus 11.6%) than any other indication ( P < 0.001). Portal vein thrombosis, location in intensive care unit, dialysis, and pre-LT diabetes ( P < 0.001 for all) are independently predictive of patient death and graft loss. Body mass index is not predictive. NASH patients undergoing simultaneous liver kidney have markedly worse 10-y patient and graft survival than liver-only (52.3% versus 62.1%). Graft loss was attributed to recurrence of NASH in <1% of patients.

Conclusions: LT for NASH is associated with relatively poor long-term patient and graft survival when compared with patients transplanted for other indications, NASH patients undergoing simultaneous liver kidney have the worst long-term outcomes.

PubMed Disclaimer

Conflict of interest statement

S.P. received research/grant funding from Intercept, Target PharmaSolutions, and Genfit. M.C. has consulted for Gilead, AbbVie, Bristol Myers, AMRA, Terns, Madrigal, Novartis, Lipocene, Metacrine, NGM Bio, and Intercept. The other authors declare no conflicts of interest.

References

    1. Sheka AC, Adeyi O, Thompson J, et al. Nonalcoholic steatohepatitis: a review. JAMA. 2020;323:1175–1183.
    1. Palmer MK, Toth PP. Trends in lipids, obesity, metabolic syndrome, and diabetes mellitus in the United States: an NHANES analysis (2003-2004 to 2013-2014). Obesity (Silver Spring). 2019;27:309–314.
    1. Cotter TG, Rinella M. Nonalcoholic fatty liver disease 2020: the state of the disease. Gastroenterology. 2020;158:1851–1864.
    1. Mikolasevic I, Filipec-Kanizaj T, Mijic M, et al. Nonalcoholic fatty liver disease and liver transplantation - where do we stand? World J Gastroenterol. 2018;24:1491–1506.
    1. Younossi ZM, Marchesini G, Pinto-Cortez H, et al. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: implications for liver transplantation. Transplantation. 2019;103:22–27.

LinkOut - more resources